New Strong Buy Stocks for September 18th
SN, ALX, BPOP, ARCAY and JSAIY have been added to the Zacks Rank #1 (Strong Buy) List on September 18, 2024.
Best Income Stocks to Buy for September 13th
BANF, ALX and BPRN made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 13, 2024.
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
ALX Oncology's Evorpacept, a first-in-class CD47 inhibitor, shows promising results in cancer treatment with reduced side effects and a favorable safety profile. Evorpacept's combination with TRP demonstrated improved response rates and longer duration of response in HER2-positive gastric and GEJ cancer trials. The ASPEN-06 trial also showed favorable results, with a 40.3% ORR in HER2-positive gastric/GEJ cancer, higher than the control group's 26.6%.
3 Highly Ranked REITs to Buy with Rate Cuts Ahead
With the possibility of multiple rate cuts back on the table this year, Real Estate Investment Trusts (REITs) may stand to benefit the most as these equities rely on debt to finance their operations and acquire properties.
Alexander's (ALX) Upgraded to Strong Buy: Here's What You Should Know
Alexander's (ALX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Income Stocks to Buy for August 9th
NREF, DKL and ALX made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 9, 2024.
Alexander's (ALX) Beats Q2 FFO and Revenue Estimates
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $3.31 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to FFO of $3.55 per share a year ago.
Alexander's Inc.: Numerous Signs Of Distress
Office REITs have gained modestly this year, but face challenges due to the WFH trend and mounting defaults in commercial real estate loans. Alexanders, Inc. is a small-cap REIT with a portfolio of office and retail properties in New York City, facing heavy indebtedness, shrinking revenues, and reliance on a single tenant. ALX faces liquidity issues, and may need to cut dividends or dilutively issue new shares, making it a risky investment for the longer term.
Three Office REITs To Sell With Weak Balance Sheets
There will likely be a major sell-off in REITs in the next 2-5 years. Weak REITs with messy balance sheets, weak forecasts for FFO growth, unsafe dividends, and/or overvaluation are likely to suffer the most damage in any downturn. This article focuses on three specific REITs that may be particularly vulnerable in a downturn.
ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
ALX Oncology valuation has dropped below $500 million, presenting new studies at venues like ASCO, reaching a point of inflection. Evorpacept is the main focus, showing promising activity signals in gastric cancer and urothelial carcinoma, with upcoming data updates and trials. Financially, ALXO has a reasonable cash pool to fund operations for the near term, with a runway of 5-6 quarters.
The Ultimate Contrarian Plays: 7 Hated Stocks Yielding Up To 12.9%
What's better than a big dividend?
